Next Generation Antibiotics to fight Antimicrobial Resistance
Madam Therapeutics is an “end of pre-clinical stage” biotech company that develops antibiotics with a novel Mechanism of action. The company managed to acquire substantial funding (€ 9.2M) by own investments, grants and donations, which led to successful finalization of the pre-clinical stage research of its lead product SAAP-148. Recently a first seed equity investment round of €1.1M was closed successfully. The company is now ready to enter into the clinical proof of concept stage. Madam Therapeutics is currently raising funds to start the preparation of the next clinical stages in 2019. After the phase I/IIa clinical study, Madam Therapeutics aims to out-license the product(s) to a larger a pharma company for further development and commercialisation.
Speaker: Leonie de Best, Chief Business Officer
Leonie de Best is Chief Business Officer at Madam Therapeutics. She has a background in Analytical Chemistry and has 20 years of extensive management experience in biotech/life science industry, of which 5 years at senior executive level (COO). Leonie has a broad experience in the management of business processes in the field of (in-vitro) diagnostic assay and pharmaceutical product development from research stage until European and US market registrations.
The audience picked Healthy Mind, Iova and PharmaCytics as their top 3 pitchers and of these the jury chose PharmaCytics as the winner of the Axon Innovation for Health Award.